Description: Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108 nM), PDGFRalpha, and PDGFRbeta (IC50=59/65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis....

BIBF 1120 is an inhibitor of the receptor tyrosine kinases VEGFR, FGFR, and PDGFR (IC50s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRalpha, and PDGFRbeta, respectively). It is selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC50s = 16-156 nM)....

Nintedanib is an orally bioavailable and potent triple angiokinase inhibitor with potential antiangiogenic and antineoplastic activities. It targets the proangiogenic pathways mediated by the the receptor tyrosine kinases VEGFR1/2/3 (IC50=13-34nM), FGFR1/2/3 (IC50=37-108nM) and PDGFRalpha/beta (IC50=59-65nM), which...